Sosei Assigns AD 923 Assets to Pharmasol

Sosei Assigns AD 923 Assets to Pharmasol Tokyo, Japan – 6 October 2009: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei R&D Ltd., its whol ly owned UK subsidiary, has entered into an agreement to assign its rights to t he assets of AD 923, an optimised, sublingual formulation of the opioid anal gesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd. (“Pharmasol”), a privately held UK company. The AD 923 development programme had previously entered Phase III clinical trials in Europe. Howeve r, due to the changes in regulatory environment, restructuring of Sosei R& D business operati on, the programme had been halted. Based on the present agr eement Sosei R&D will re ceive payments from Pharmasol based on revenues arising fr om the commercialization of these assigned assets. -Ends- Enquiries: Sosei Group Corporation Kojimachi Tsuruya Hachiman Bldg. 5F 2-4 Kojimachi, Chiyoda-ku Tokyo 102-0083 Japan Hidetoshi Torami E-mail: [email protected] Tel: +81-3-5210-3399 Fax: +81-3-5210-3291 Sosei R&D Ltd 1F London BioScience Innovation Centre 2 Royal College Street, London NW1 0NH Dr Michael Murray, Managing Director E-mail: [email protected] Tel: +44-20-7691-2081 Fax: +44-20-7209-2484 Editor’s notes: About Sosei Sosei Group is a leading international biopharmaceutical company with significant expertise in product discove ry and development. It has established a reduced risk business model prim arily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmac eutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit www.sosei.com About Pharmasol Pharmasol Corporation engages in the contract manufactu ring, packaging, and warehousing of aerosols, liquids, gel s, and lotions for the health care and cosmetics industries. It al so offers consultancy services, including research and development, purchasing, and marketing. For further information about Pharmasol, please visit www.pharmasol.co.uk

The release as fetched from its publisher. nxera.life ↗